Search results
Results from the WOW.Com Content Network
To use this userbox template, place the following line of Wikitext on your user page: {{User multiple myeloma|year1|month1|date1|year2|month2|date2}} where: year1 is the optional 4-digit year number of the user's initial diagnosis. month1 is the optional month number of the user's initial diagnosis.
Multiple myeloma is the second-most prevalent blood cancer (10%) after non-Hodgkin's lymphoma. [154] It represents about 1.8% of all new cancers and 2.1% of all cancer deaths. [7] Multiple myeloma affects slightly more men than women.
A clinical pathway is a multidisciplinary management tool based on evidence-based practice for a specific group of patients with a predictable clinical course, in which the different tasks (interventions) by the professionals involved in the patient care are defined, optimized and sequenced either by hour (ED), day (acute care) or visit (homecare).
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
The International Myeloma Foundation (IMF) is an American non-profit organization serving patients with myeloma, a cancer of plasma cells in the bone marrow. The IMF also provides support and information for family members, caregivers of myeloma patients, physicians and nurses.
Other areas of concentration include bone marrow transplants, stem cell transplantation, lymphoma, leukemia, multiple myeloma, neuro-oncology, cutaneous malignancy, gastrointestinal, geriatric, head and neck, thoracic, urologic, breast, and gynecologic. [2] As of 2023, Andre Goy is chair and Chief Physician Officer. [3] [4] [5]
Smouldering myeloma is a disease classified as intermediate in a spectrum of step-wise progressive diseases termed plasma cell dyscrasias.In this spectrum of diseases, a clone of plasma cells secreting monoclonal paraprotein (also termed myeloma protein or M protein) causes the relatively benign disease of monoclonal gammopathy of undetermined significance.
MRD tests also make use of this time, but the tests are much more sensitive. When past patients were studied, patients with high levels at this stage – here "high" means often leukaemia more than 1 cell in 1000 – were at risk of relapse. Patients with levels below 1 in 100,000 were very unlikely to relapse. For those in between, some relapsed.